Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2021 16:04 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports First Quarter 2021 Financial Results

– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion...
October 07, 2020 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH

SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...